Columns

Good News for CLN1 Disease and a Sprint to the Finish

Last week, Taysha Gene Therapies announced the company has entered into license and inventory purchase agreements with Abeona Therapeutics for ABO-202, an adeno-associated virus (AAV) gene therapy for CLN1 disease (Batten disease). In the longest race, this news is a huge leap forward for children…

When Is It OK to Quit Fighting Rare Disease?

If she were still alive, my younger sister would have celebrated her 22nd birthday today. Instead, Taylor died from CLN1 disease (Batten disease) in September 2018, more than 12 years after her diagnosis. Long before I said goodbye to my sister, I knew all of the work our charity,…

What Can COVID-19 Teach Us About Batten Disease?

Can you remember a stranger year than 2020? I was a college sophomore on 9/11, but while that tragedy mostly united Americans, the COVID-19 pandemic and growing racial tensions have proved divisive. And while neither of these crises directly relates to rare disease, I can’t help…

Batten Disease: Life, Interrupted

The message landed in my inbox just before lunch on Day 61 of the quarantine. I was working from home while making lunch for my 1-year-old son, juggling content strategy with clementines. Shuttling between my makeshift standing desk and Jack’s already messy highchair, I glanced down at my phone quickly,…

Rare Disease Therapy Development: Finding a Way Forward

Gaining access to lifesaving or even life-altering treatments has never been easy for many rare disease patients — including those with Batten disease. But the landscape is changing. What felt like a slow crawl in my sister’s lifetime (Taylor was diagnosed with CLN1 disease in 2006) is now, if not…